Study of a new shot for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have multiple myeloma that has returned or not responded to at least one prior treatment, including a proteasome inhibitor, an immunomodulator, and a CD38 antibody.
- Your disease has measurable signs and has progressed within 12 months of your last treatment.
- You are willing to use effective contraception during the study and for 6 months after.
- You do not have certain other plasma cell disorders or active infections.
- You have not had certain prior treatments or vaccines within specified timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable drug, TQB2029, for people with multiple myeloma. It aims to see if the drug is safe and effective, and may be an option if you have measurable disease and are in relatively good health.
This study tests a new treatment called TQB2934 for people with multiple myeloma that has returned or hasn't gotten better after treatment. The goal is to see if it can help control the disease.
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called SHR-3836 for patients with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if the drug is safe and how it works against the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.